PubMed Health⌕ Search

Biomedical subjects

K Sampi

Publications and source records attributed to K Sampi.

At least 73 records · Page 4Linked to original sources
PubMed1985

[Phase II study of VP-16 (capsule) in malignant lymphomas. A cooperative study].

A new semisynthetic podophyllotoxin derivative VP-16 has been evaluated in a phase II study on malignant lymphomas. The drug was administered orally by capsule at a dose of 100mg twice a day for 5 consecutive days at 3-4-week intervals to a total of 53 patients. Objective responses were noted in 9 patients (25%), 4 with CR and 5 with PR, out of 36 patients with non-Hodgkin's lymphoma, while none of 5 patients with Hodgkin's disease responded. Two of 5 patients with adult T-cell lymphoma attained a PR. Overall objective response rate was 24%. Dose-limiting toxicity was hematologic and alopecia was also observed. Gastrointestinal toxicity was moderate. These results demonstrated that VP-16 administered as an oral capsule is effective against malignant lymphomas and suggested a lack of clinical cross-resistance to standard chemotherapeutic agents.

Administration, Oral↗
PubMed1985

[Empiric therapy with piperacillin plus amikacin for febrile patients with cancer--with emphasis on granulocytopenia].

Between August 1979 and December 1983 one hundred episodes of fever in 70 patients with cancer, most of whom had granulocytopenia, were treated empirically with a combination of piperacillin (4.0g, every 6 hours) and amikacin (200mg, every 6 hours) at Saitama Cancer Center. Profound granulocytopenia (less than 100/mm3 of granulocytes) was present at the beginning of treatment in 40% of episodes. Oral absorbable or nonabsorbable antibiotics were used in 57 febrile episodes. WBC transfusion was not given. The response rate for all documented infections was 58.1%, including 8 of 9 (88.8%) episodes of bacteremia. The majority of infections with identified organisms were caused by aerobic gram-negative pathogens including P. aeruginosa (8 cases), Klebsiella spp. (3 cases), E. coli (4 cases), Proteus mirabilis (2 cases) and serratia spp. (3 cases). The response rate of gram-negative bacillary infections was 55% Pneumonia with a response rate of 21.1% responded less satisfactorily than all other types of infection. The response rate for profound persistent granulocytopenia (less than 100/mm3 granulocytes without a rise during therapy) was 45.5%. The most common adverse effect was hepatotoxicity (16 episodes). Nephrotoxicity occurred in 4 patients and skin rash in 2 patients.

Acute Disease↗
PubMed1985

[Phase II trial of mitoxantrone in patients with relapsed and refractory acute leukemia].

Mitoxantrone, a new anthracenedione, was administered to twenty-five evaluable patients with relapsed or refractory acute leukemia between January 1982 and September 1984. Two patients were not evaluable because of early death. There were 18 males and 7 females with a median age of 42 yrs (range 6-70 yrs). Four of these were less than 14 yrs and 6 more than 55 yrs. The initial dose employed was 3 mg/m2/day X 5 days. Eventually a starting dose of 10 mg/m2 X 5 days was used. Among 16 patients with acute nonlymphocytic leukemia, there was one complete and 3 partial remissions. One of 4 patients with acute lymphocytic leukemia achieved a complete remission. Also, a complete remission was obtained in a patient with T-cell lymphoma/leukemia. The overall remission rate was 24% with a complete remission rate of 12%. Remissions occurred at doses of more than 6 mg/m2/day X 5 days. Four of the 6 patients who had attained a remission received one of the anthracyclines. Bone marrow depression was the dose-limiting factor. Mucositis occurred in 6 patients to whom higher doses were administered. This mucositis was thought to be due to drug-related toxicity. The trials were too short to evaluate possible cardiac toxicity. These data indicate that mitoxantrone is a promising single drug for the treatment of relapsed or refractory acute leukemia.

Acute Disease↗
PubMed1984

[Adriamycin-based combination chemotherapy in the treatment of advanced malignant lymphoma. A progress report].

Forty-six previously untreated patients with advanced Hodgkin's disease (3 cases) and non-Hodgkin's lymphoma (Intermediate grade of the Working Formulation) were treated with Adriamycin-based combination chemotherapy at Saitama Cancer Center between January 1977 and December 1982. The median age was 55 years (range, 18-74 years), with 10 patients (22%) 66 years of age or older. The overall complete response rate was 23 of 46 or 50%. The complete response rate of stage III (62.5%) was superior to that (36.4%) of stage IV, but there was no statistical difference between stage III and IV. The complete response in patients with extranodal lymphoma including Waldeyer's ring primary was 9 of 16 (56.2%), while 11 of 27 patients (40.7%) with nodal lymphoma had complete responses. The median survival for all patients was 26 months. The survival curve of complete responders became flat at 41 months and was well sustained with an actuarial survival of 79%. The survival at 5 years was 60% in patients who had stage III and 26% in patients who had stage IV (p greater than 0.05). Congestive heart failure resulting in death occurred in one case given 315mg /m2 of adriamycin and then 90 mg/m2 of mitoxantrone.

Adolescent↗
PubMed1984

[Plasma concentration of peplomycin following intravenous infusion and subcutaneous infusion in patients with malignancies].

Five mg of peplomycin was administered continuously for 24 hours by intravenous or subcutaneous infusion. Subcutaneous administration of peplomycin was performed done with the use of an SP-5 microinfusion pump made by the in Nipro Company. The plasma concentration after intravenous infusion was 0.0106 +/- 0.039 microgram/ml, while that after subcutaneous infusion was 0.131 +/- 0.037 microgram/ml. There was no statistical significance between the differences observed for intravenous and subcutaneous infusion.

Antibiotics, Antineoplastic↗
PubMed1984

[Combination chemotherapy of CIS-diamminedichloroplatinum (II) and fluoropyrimidine derivatives for advanced gastric cancer: a preliminary report].

A total of thirteen patients with histologically-proved adenocarcinoma of stomach took part in this study at Saitama Cancer Center between July 1982 and September 1983; nine patients were considered evaluable. There were 7 male and 2 female patients with a median age of 52 yrs (range 42-75) and a median performance status of 3 (range 2-4). Patients were treated with a two drug combination of cis-diammine dichloroplatinum (II) and fluoropyrimidine derivatives (tegafur, cormobur ). Three out of 9 evaluable patients (33.3%) had a partial response which lasted 10 months. 6+ months, and 5+ months, respectively. The major toxic effect was a gastrointestinal symptom which was generally manageable. Myelosuppression was mild.

Adenocarcinoma↗
PubMed1984

[Combination chemotherapy of nicardipine and vindesine sulfate, cis-diammine dichloroplatinum (II) for patients with advanced esophageal carcinoma].

Since calcium (Ca) antagonist enhances the antitumor effect of vinca alkaloid in vitro, The authors attempted to combine nicardipine (Ca antagonist) with vindesine sulfate (VDS) and cis-diammine dichloroplatinum (II)(CDDP) for treatment of two patients with advanced esophageal carcinoma who were considered to be resistant to two courses of combination chemotherapy of VDS and CDDP. In the first case nicardipine was given orally and for only one day at a dose of 60 mg followed by 40 mg two and a half hours later. Thirty minutes after 60 mg of nicardipine, 3 mg of VDS on day 1, and 50 mg of CDDP (repeated for 3 days) were given. The maximum plasma concentration of nicardipine was 834.0 mg/ml, and the patient showed a partial response. In the second case nicardipine was given intravenously at a dose of 10 mg/body/hour for 8 hours which was repeated for 3 days. The same dose of VDS and CDDP as the first case was started the second day. The maximum concentration of nicardipine was 254.3 ng/ml, and this patient did not show any response. These results may suggest that a sufficient plasma concentration of nicardipine would obtained some response even in solid tumors.

Antineoplastic Combined Chemotherapy Protocols↗
PubMed1984

[Effect of cis-diammine dichloroplatinum, vindesine sulfate combination chemotherapy for advanced esophageal carcinoma].

Eleven patients with advanced squamous cell carcinoma of the esophagus were treated with a two-drug combination of cis-diammine dichloroplatinum and vindesine sulfate at Saitama Cancer Center between July 1982 and September 1983. Median age was 71 years old (range: 47-48) and 8 patients were greater than 70 years old. Median performance status was 3 (range: 1-4) by Koyama -Saito Criteria. Male female ratio was 6:5. Of the 11 patents, three obtained partial response (27.3%), lasting 8 weeks, 20 weeks+, and 42 weeks-, respectively, and three patients had minor response (27.3%). The major toxic effects including myelosuppression, nausea and vomiting were in general manageable.

Aged↗
PubMed1984

Differentiation in vitro of human myelogenous leukemia cells from patients in relapse.

Leukemia cells from patients with acute myeloid leukemia in relapse were treated with various inducers of differentiation of human myeloid leukemia cell lines. Leukemia cells in primary culture from most, but not all, patients underwent morphological, cytochemical and biochemical changes after treatment with inducers of differentiation such as 12-O-tetradecanoylphorbol-13-acetate (TPA), retinoic acid, actinomycin D, aclarubicin, and alkyl lysophospholipid. The most effective inducer varied from specimen to specimen. Leukemia cells from patients in relapse were compared with those from untreated patients. The responsiveness to TPA of leukemia cells from patients in relapse was similar to that of leukemia cells from untreated patients. However, retinoic acid or actinomycin D resistance was more frequently observed in leukemia cells from patients in relapse than in those from patients before initial therapy. This is the first report to indicate that leukemic cells from relapsed patients who are resistant to cytotoxic chemotherapeutic drugs can be induced to differentiate into mature cells by appropriate inducers. However, the responsiveness to inducers of leukemia cells from patients in relapse is not the same as that of leukemia cells before therapy.

Adolescent↗
PubMed1983

Primary chemotherapy followed by radiotherapy for localized non-Hodgkin's lymphomas: a preliminary report.

Twenty-eight evaluable patients with clinical stage I-II of non-Hodgkin's lymphoma were treated with primary chemotherapy followed by involved field radiotherapy. The frequency of the follicular versus diffuse histological pattern was 14.3 versus 85.7%, and 24/28 (86%) of patients were in stage II. No lymphoma examined was identified as T-cell in origin. A complete response was obtained in 21 (78%) of 27 patients with measurable disorder. [Gastrectomy rendered one patient disease-free survival, and one partially responded showing a complete response after radiotherapy.] Sixteen (76%) of the 21 employed for complete response. After 36 months, elapsed disease-free survival was rated at 100% together with actuarial survival of all patients at 81%. Chemotherapy contributed to reduce the radiation dosage to 3000 rads and to control the areas infiltrated with preexisting tumors. These findings, although the median follow-up time in our study remains short (28 months), provide a strong rationale for further clinical trials of primary chemotherapy, followed by regional radiotherapy for localized stages of non-Hodgkin's lymphomas.

Adult↗
PubMed1983

Possible differentiation of human acute myeloblastic leukemia cells by daily and intermittent administration of aclacinomycin-A.

A rapid decrease of myeloblasts and a remarkable increase of mature neutrophils, mostly with Pelger anomaly, were observed in the peripheral blood of a 51-year-old woman with terminal acute myeloblastic leukemia during 16 days of daily i.v. administration of 20 mg aclacinomycin-A (ACM-A). When the same dose was administered later on three consecutive days each week, a similar hematore neutrophils, mostly with Pelger anomaly, were observed in the peripheral blood of a 51-year-old woman with terminal acute myeloblastic leukemia during 16 days of daily i.v. administration of 20 mg aclacinomycin-A (ACM-A). When the same dose was administered later on three consecutive days each week, a similar hematore neutrophils, mostly with Pelger anomaly, were observed in the peripheral blood of a 51-year-old woman with terminal acute myeloblastic leukemia during 16 days of daily i.v. administration of 20 mg aclacinomycin-A (ACM-A). When the same dose was administered later on three consecutive days each week, a similar hematological change occurred again. An increase of myeloblasts observed between the third and the fifth week of this intermittent schedule was accompanied by that of mature neutrophils. Thrombopenia and anemia did not improve significantly. These findings may indicate the induction of leukemic myeloblasts by ACM-A into mature neutrophils. Administration of relatively small dose anthracyclines including ACM-A may be another potential choice in the treatment of refractory acute non-lymphocytic leukemia (ANLL) or ANLL after relapse.

Aclarubicin↗